International variation in overall survival linked to differences in childhood tumor stage distribution for some cancer types and regions.

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...

The National Comprehensive Cancer Network ® (NCCN ® ) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN ...

Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the ...

Years of caring for children with solid tumors and looking into the eyes of parents starved for hope have led Catherine Bollard to what she calls the most important moment of her career. Children’s ...

Liquid biopsies, which test body fluids that contain cancerous material, including circulating tumor DNA (ctDNA), are a ...

Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...

In our three-part series -- Fighting For Hope: Pediatric Cancer's Funding Crisis -- 3News' Maureen Kyle follows the journey of young patients and their families as they navigate pediatric cancer. This ...

SAN ANTONIO - Every year, about 15,000 children in the United States are diagnosed with cancer, a staggering number highlighted on International Childhood Cance ...

St. Jude Children’s Research Hospital scientists and multinational collaborators created AI-powered M-PACT to facilitate next ...

CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

St. Jude Children’s Research Hospital scientists have created AI-powered M-PACT to facilitate next-generation classification of pediatric brain tumors by liquid biopsy.